Australian Competition and Consumer Commission Pushes Forward GSK-Pfizer Consumer Healthcare Business
The GlaxoSmithKline’ deal seeking to purchase & combine Pfizer’s consumer healthcare business with their own has recently received approval from Australia’s antitrust regulator recently called the Australian Competition and Consumer Commission (ACCC.) It was reported that the ACCC anticipates that the new partnership will face significant competition from generic players in the market because generic products are much cheaper in comparison. 68 percent of the new venture will be owned by GlaxoSmithKline.
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!